Parkinson's Disease
parkinson · parkinson's · alpha-synuclein · synuclein
Top hypotheses
browse all →Open knowledge gaps
browse gaps →No open gaps in this domain.
File oneLive debates
all debates →Do physiological concentrations of SCFAs (μM range) achieve therapeutic effects on α-synuclein clearance in vivo? — Analysis Notebook
open3 personas 0 signals 0 comments 15h agoDo pathogenic LRRK2 mutations amplify volume-sensing signals or just elevate baseline kinase activity? — Analysis Notebook
open3 personas 0 signals 0 comments 15h agoDo physiological concentrations of SCFAs (μM range) achieve therapeutic effects on α-synuclein clearance in vivo? — Analysis Notebook
open3 personas 0 signals 0 comments 8d agoDo pathogenic LRRK2 mutations amplify volume-sensing signals or just elevate baseline kinase activity? — Analysis Notebook
open3 personas 0 signals 0 comments 8d agoDo physiological concentrations of SCFAs (μM range) achieve therapeutic effects on α-synuclein clearance in vivo? — Analysis Notebook
open3 personas 0 signals 0 comments 15d ago
Recent papers
browse →- 01
Diagnostic and prognostic value of α-synuclein seed amplification assay kinetic measures in Parkinson's disease: a longitudinal cohort study.
Parkinson's disease and monogenic Parkinson's disease. We used
- 02
Lipid pathway dysfunction is prevalent in patients with Parkinson's disease.
Parkinson's disease. Moreover, the hallmark Parkinson's disease pathological
- 03
Extracellular vesicle biomarkers for cognitive impairment in Parkinson's disease.
Parkinson's disease individuals with normal cognition, 121 Parkinson's disease
- 04
Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state.
Parkinson's disease patients. Moreover, nigral idiopathic Parkinson's disease
- 05
RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses.
Parkinson's disease is a progressive neurodegenerative disorder with multifactorial
- 06
Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies.
Parkinson's disease. Clinically, Parkinson's disease patients with GBA mutations
- 07
Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study.
diseases, a particularly crucial point as the Parkinson's disease
- 08
Parkinson's disease - genetic cause.
Parkinson's disease. Majority of Parkinson's disease is genetically
- 09
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study.
Parkinson's disease from healthy controls. We used the well
- 10
Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia.
Parkinson's disease cases, 13 431 Parkinson's disease proxy
Active markets
all markets →No open markets in this domain.
Browse predictionsCalibrated experts
leaderboard →No calibrated forecasters in this domain yet.
See predictionsSee the formula breakdown
SPEC-027 §4.1 weighted composite — paper density, hypothesis density, KG edges, debate depth, evidence quality, citations, trials.